AR024390A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
AR024390A1
AR024390A1 ARP000103010A ARP000103010A AR024390A1 AR 024390 A1 AR024390 A1 AR 024390A1 AR P000103010 A ARP000103010 A AR P000103010A AR P000103010 A ARP000103010 A AR P000103010A AR 024390 A1 AR024390 A1 AR 024390A1
Authority
AR
Argentina
Prior art keywords
alkoxy
compound
independently
unsubstituted
hydroxy
Prior art date
Application number
ARP000103010A
Other languages
English (en)
Original Assignee
Nikem Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikem Research Srl filed Critical Nikem Research Srl
Publication of AR024390A1 publication Critical patent/AR024390A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Un compuesto de la formula (1) o una de sus sales, o uno de sus solvatos, en la que: R1 y R2 cada uno independientemente, representa alcoxi C1-6 o halo; R3y R4 cada uno independientemente, representan hidrogeno, alcoxi C1-6, arilalcoxi C1-6,hidroxi, carboxi-alcoxi C1-6, hidroxi-alcoxi C1-6, dihidroxi-alcoxi C1-6, mono- y di alquil C1-6-amino-alcooxi C1-6 o amino-alcoxi C1-6 y R5 representa -NRsRt, cada uno independientemente representanhidrogeno, alquilo C1-6 sustituido o nosustituido, o heter ociclilo sustituido o no sustituido, un procedimiento para la preparacion de dicho compuesto, unacomposicion farmacéutica que contiene dicho compuesto y el uso del compuesto o de la composicion en medicina. Los compuestos actuaninhibiendo selectivam entela actividad de los osteoclastos en la resorcion osea.
ARP000103010A 1999-06-18 2000-06-16 Nuevos compuestos AR024390A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914371.1A GB9914371D0 (en) 1999-06-18 1999-06-18 Novel compounds

Publications (1)

Publication Number Publication Date
AR024390A1 true AR024390A1 (es) 2002-10-02

Family

ID=10855696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103010A AR024390A1 (es) 1999-06-18 2000-06-16 Nuevos compuestos

Country Status (30)

Country Link
US (2) US6787550B1 (es)
EP (1) EP1212317B1 (es)
JP (1) JP2003503490A (es)
KR (1) KR100701109B1 (es)
CN (1) CN1179960C (es)
AR (1) AR024390A1 (es)
AT (1) ATE276245T1 (es)
AU (1) AU768726B2 (es)
BR (1) BR0011708A (es)
CA (1) CA2376657A1 (es)
CO (1) CO5200757A1 (es)
CZ (1) CZ301697B6 (es)
DE (1) DE60013859T2 (es)
DK (1) DK1212317T3 (es)
ES (1) ES2226870T3 (es)
GB (1) GB9914371D0 (es)
GC (1) GC0000341A (es)
HK (2) HK1048468B (es)
HU (1) HUP0202049A3 (es)
IL (2) IL147012A0 (es)
MX (1) MXPA01013277A (es)
MY (1) MY129425A (es)
NO (1) NO322313B1 (es)
NZ (1) NZ516131A (es)
PL (1) PL352964A1 (es)
PT (1) PT1212317E (es)
TR (1) TR200103683T2 (es)
TW (1) TWI248440B (es)
WO (1) WO2001002388A1 (es)
ZA (1) ZA200200177B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615575B2 (en) 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2004259703A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
ITMI20040875A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici utili per il trattamento della resistenza agli agenti antitumorali
EP1799696B1 (en) 2004-09-17 2008-11-12 IDENIX Pharmaceuticals, Inc. Phosphoindoles as hiv inhibitors
WO2006041874A2 (en) * 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for alzheimer's disease
US7833805B2 (en) * 2004-10-21 2010-11-16 University Of Cincinnati Selectively permeable membranes on porous substrates
JP5070050B2 (ja) * 2005-07-20 2012-11-07 正徳 染井 トリプトファン誘導体及びその用途
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
BRPI0616994A2 (pt) * 2005-08-15 2011-07-05 Irm Llc compostos e composições como miméticos de tpo
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
EP1779848A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
CA2637375A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2637373A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN101378740A (zh) 2006-02-02 2009-03-04 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
WO2008008887A2 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
AU2007305447A1 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc Enantiomerically pure phosphoindoles as HIV inhibitors
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2396081T (pt) 2009-02-16 2017-07-11 Nogra Pharma Ltd Compostos alquilamido e suas utilizações
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
PL2614052T3 (pl) 2010-09-08 2015-06-30 Bristol Myers Squibb Co Nowe analogi piperazyny jako środki przeciw wirusowi grypy o szerokim spektrum
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
BR112014026160A2 (pt) 2012-04-18 2017-07-18 Nogra Pharma Ltd métodos para tratar intolerância à lactose
EA202192207A1 (ru) 2019-02-08 2021-10-27 Ногра Фарма Лимитед Способ получения 3-(4'-аминофенил)-2-метоксипропионовой кислоты и ее аналогов и промежуточных соединений
CN113024432A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种氨磺必利药典杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
TR199700625T1 (xx) * 1995-01-10 1998-02-21 Smithkline Beecham S.P.A. Osteoporoz (kemik erimesi) tedavisinde yararl� olan indol t�revleri.
AU3620597A (en) 1996-07-09 1998-02-02 Smithkline Beecham Laboratoires Pharmaceutiques Indole derivatives for the treatment of osteoporosis
CN1208333C (zh) 1997-12-24 2005-06-29 Nikem研究有限公司 主要用于治疗骨质疏松的吲哚衍生物

Also Published As

Publication number Publication date
HUP0202049A3 (en) 2003-12-29
CO5200757A1 (es) 2002-09-27
CZ301697B6 (cs) 2010-05-26
JP2003503490A (ja) 2003-01-28
US20040235930A1 (en) 2004-11-25
EP1212317B1 (en) 2004-09-15
AU768726B2 (en) 2004-01-08
DK1212317T3 (da) 2005-01-24
PL352964A1 (en) 2003-09-22
DE60013859D1 (de) 2004-10-21
EP1212317A1 (en) 2002-06-12
NO322313B1 (no) 2006-09-11
US6787550B1 (en) 2004-09-07
MY129425A (en) 2007-03-30
ZA200200177B (en) 2003-09-23
ATE276245T1 (de) 2004-10-15
TR200103683T2 (tr) 2003-01-21
PT1212317E (pt) 2005-02-28
GC0000341A (en) 2007-03-31
CN1179960C (zh) 2004-12-15
BR0011708A (pt) 2002-05-21
CA2376657A1 (en) 2001-01-11
GB9914371D0 (en) 1999-08-18
AU5816500A (en) 2001-01-22
KR20020025079A (ko) 2002-04-03
MXPA01013277A (es) 2002-06-04
HK1048468B (zh) 2005-07-29
TWI248440B (en) 2006-02-01
IL147012A0 (en) 2002-08-14
WO2001002388A1 (en) 2001-01-11
NO20016149D0 (no) 2001-12-17
DE60013859T2 (de) 2005-09-29
NO20016149L (no) 2001-12-17
NZ516131A (en) 2003-10-31
CZ20014496A3 (cs) 2002-07-17
HUP0202049A2 (hu) 2002-11-28
HK1049164A1 (zh) 2003-05-02
CN1370159A (zh) 2002-09-18
ES2226870T3 (es) 2005-04-01
KR100701109B1 (ko) 2007-03-29
IL147012A (en) 2007-06-03
HK1048468A1 (en) 2003-04-04

Similar Documents

Publication Publication Date Title
AR024390A1 (es) Nuevos compuestos
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
NL350075I2 (es)
AR245447A1 (es) Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas.
AR034475A1 (es) Derivados de androstano antiinflamatorios
ATE337293T1 (de) Stabile salze neuartiger derivative von 3,3- diphenylpropylaminen
UY24555A1 (es) Nuevos compuestos
PA8495101A1 (es) Derivados de 13-metileritromicina
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
DK0390114T3 (da) Undertrykkelse af syntese og udskillelse af parathyroidhormoner med vitamin D3 derivater
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
ECSP045291A (es) Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1257552T3 (da) Xanthinderivater, mellemprodukter og anvendelse til behandling af osteoporose
ES2043070T3 (es) Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
CR6503A (es) Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano
ES2061564T3 (es) Nuevo procedimiento para la preparacion de derivados de 6,7-diacil-7-desacetilforscolina.
AR015147A1 (es) Compuestos de 1-bis-trifluorometilbenzoil-2-indolilmetil-4-bencilamino-metil-piperazina, medicamentos que los contienen, y procedimiento para supreparacion
ES2052206T3 (es) Procedimiento de preparacion de nuevos derivados de benzotiazolinona y las composiciones farmaceuticas que los contienen.
CO4750648A1 (es) 5-naftalen-1-il-1,3 dioxanos, su preparacion y composiciones farmaceuticas que los contienen
ES8800938A1 (es) Procedimiento para preparar derivados berbanicos biologicamente activos.
ES2099973T3 (es) Derivados de ureido-acetamida su preparacion y los medicamentos que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal